Fassnacht Martin, Hahner Stefanie, Polat Buelent, Koschker Ann-Cathrin, Kenn Werner, Flentje Michael, Allolio Bruno
University of Wuerzburg, Department of Internal Medicine I, Endocrine and Diabetes Unit, Wuerzburg, Germany.
J Clin Endocrinol Metab. 2006 Nov;91(11):4501-4. doi: 10.1210/jc.2006-1007. Epub 2006 Aug 8.
Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation. Although radiotherapy is often considered ineffective in the treatment of ACC, the limited number of available studies does not support this statement.
The objective of the study was investigation of adjuvant tumor bed irradiation in the treatment of ACC.
We performed a retrospective analysis.
The German ACC Registry (n = 285) was screened for patients who had received tumor bed radiotherapy in an adjuvant setting (no macroscopic evidence for residual disease after surgery). Fourteen patients without distant metastases (World Health Organization stage I, one patient; stage II, seven; stage III, three; and stage IV, three) were matched with 14 patients for resection status, adjuvant mitotane treatment, stage, and tumor size. Median follow-up of patients still alive (n = 15) was 37 months.
Survival without local recurrence and disease-free survival was the main outcome measure.
Local recurrence was observed in two of 14 patients in the radiotherapy group and in 11 of 14 control patients. The probability to be free of local recurrence 5 yr after surgery differed significantly [79% (95% confidence interval, 53-100) vs. 12% (0-30); P < 0.01]. However, disease-free and overall survival were not significantly different between the two groups. Acute adverse events related to radiotherapy were mostly mild. One patient developed a partial Budd-Chiari syndrome.
These data from the largest series of ACC patients treated with adjuvant tumor bed irradiation suggest that radiotherapy is effective in reducing the high rate of local recurrence in ACC. A randomized trial in high-risk patients is needed to further evaluate the efficacy of radiotherapy as an adjuvant treatment option in ACC.
肾上腺皮质癌(ACC)局部肿瘤复发很常见,是再次手术最常见的原因。尽管放射治疗通常被认为对ACC治疗无效,但现有研究数量有限,并不支持这一说法。
本研究的目的是调查辅助性肿瘤床照射在ACC治疗中的作用。
我们进行了一项回顾性分析。
对德国ACC登记处(n = 285)进行筛查,寻找在辅助治疗中接受过肿瘤床放疗的患者(术后无残留疾病的宏观证据)。14例无远处转移的患者(世界卫生组织I期,1例;II期,7例;III期,3例;IV期,3例)与14例患者在切除状态、辅助米托坦治疗、分期和肿瘤大小方面进行匹配。仍存活患者(n = 15)的中位随访时间为37个月。
无局部复发生存和无病生存是主要观察指标。
放疗组14例患者中有2例出现局部复发,对照组14例患者中有11例出现局部复发。术后5年无局部复发的概率有显著差异[79%(95%置信区间,53 - 100)对12%(0 - 30);P < 0.01]。然而,两组间无病生存和总生存无显著差异。与放疗相关的急性不良事件大多为轻度。1例患者发生了部分布加综合征。
这些来自接受辅助性肿瘤床照射的最大系列ACC患者的数据表明,放疗可有效降低ACC的高局部复发率。需要对高危患者进行随机试验,以进一步评估放疗作为ACC辅助治疗选择的疗效。